Targeted Hyperthermia Value Position Targeted Hyperthermia as a less invasive, safer, and potentially lower-cost cancer therapy that complements or substitutes traditional treatments like surgery, chemotherapy, and radiation, creating cross-selling opportunities with hospitals and cancer centers seeking cost-effective options.

Strategic Partnerships Leverage past collaborations with SomaLogic and NanoHybrids to identify potential research institutions, biotech partners, and contract manufacturers that can advance clinical trials, scale production of SivaRods, or co-develop related photothermal technologies.

Funding and Milestones Monetize progress by aligning with investors and strategic buyers who value milestone-based earnouts, given the existing funding level and performance-driven share-based acquisition considerations, while highlighting near-term milestones that could trigger additional equity or licenses.

Market Readiness and Niche Focus Emphasize the niche yet scalable oncology solution targeting solid tumors with selective tumor heating to attract specialty hospital networks, cancer centers, and government-funded programs seeking advanced, safer, and potentially lower-cost therapies.

Technical and Regulatory Narrative Develop a compelling technical dossier and regulatory roadmap showcasing SivaRods photothermal therapy, clinical feasibility, safety profile, and manufacturing readiness to win interest from clinical trial partners, feasibility studies, and early-adopter sites.